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Abstract Multimodal neuroimaging is increasingly used
in neuroscience research, as it overcomes the limitations of
individual modalities. One of the most important applica-
tions of multimodal neuroimaging is the provision of vital
diagnostic data for neuropsychiatric disorders. Multimodal
neuroimaging computing enables the visualization and
quantitative analysis of the alterations in brain structure
and function, and has reshaped how neuroscience research
is carried out. Research in this area is growing exponen-
tially, and so it is an appropriate time to review the current
and future development of this emerging area. Hence, in
this paper, we review the recent advances in multimodal
neuroimaging (MRI, PET) and electrophysiological (EEG,
MEG) technologies, and their applications to the neu-
ropsychiatric disorders. We also outline some future
directions for multimodal neuroimaging where researchers
will design more advanced methods and models for neu-
ropsychiatric research.
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1 Introduction
Neuroimaging has advanced rapidly in the past two dec-
ades. The advanced non-invasive neuroimaging techniques,
e.g., magnetic resonance imaging (MRI), positron emission
tomography (PET), electroencephalography (EEG), and
magnetoencephalography (MEG), have enabled the visu-
alization and analysis of the brain function and structure in
unprecedented detail and transformed the way we study the
nervous system under normal and pathological conditions
[1], particularly neuropsychiatric disorders including neu-
rological and psychiatric disorders that affect the nervous
system [2–4].
In the US, President Obama’s announcement of the ‘Brain
Research through Advancing Innovative Neurotechnologies
(BRAIN) Initiative’ on his state of the union address on April
2013 fueled resurgent interest in the neuroscience with a
bold commitment to better understand the brain over the
forthcoming decade [4]. Similar projects have been under-
taken in the European Union [5] and Asia [6].
Multimodal neuroimaging, which we declare as the
summation of information from different neuroimaging
modalities, has become one of the major drivers in neu-
roimaging research due to the recognition of the clinical
benefits of multimodal data [7, 8], and the better access to
hybrid devices, e.g., PET/CT [9, 10], PET/MRI [11], and
PET/MRI/EEG [12]. Multimodal neuroimaging data can
either be obtained from simultaneous imaging measure-
ment (EEG/fMRI [13], PET/CT[14]), or integration of
separate measurements (PET and sMRI [15], sMRI and
dMRI [16], fMRI and dMRI [17]).
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Multimodal neuroimaging advances neuroscience
research, i.e., neurology, psychiatry, neurophysiology, and
neurosurgery, by overcoming the limitation of individual
modalities and by allowing a more comprehensive picture
of the brain. For instance, we can jointly analyze the
structure and function using the data provided by PET/CT
and PET/MRI; EEG combined with functional MRI (fMRI)
improves the spatiotemporal resolution that cannot be
achieved by the single modality alone. Multimodal neu-
roimaging can also cross-validate findings from different
sources and identify associations and patterns, e.g.,
causality of brain activity can be deduced by linking
dynamics in different imaging readings. It can provide
access, in an experimental setting, to determine the roles of
different brain areas from multiple perspectives.
The growth of neuroimaging has spurred a parallel
development of multimodal neuroimaging computing,
which focuses on computational analysis of multimodal
neuroimaging data, including pre-processing, feature
extraction, image fusion, machine learning, visualization,
and post-processing. These computational advances help to
address the variations in spatiotemporal resolution and
merge the biophysical/biochemical information in images
[18].
We conducted a search on PubMed using the keywords
‘multimodal AND neuroimaging’ up to ‘31 Dec 2014.’
There were 1461 relevant publications retrieved from the
database. Figure 1 illustrates how multimodal neuroimag-
ing in neuroscience research has rapidly expanded over the
past 10 years. In 2004, there were 30 publications, and in
2014, there were close to 300 (indicated by the green area).
There is a wide range of applications of multimodal neu-
roimaging, clinical and non-clinical, including building a
brain machine interface (BMI) [19], tracing neural activ-
ities and information pathways [20], mapping mind and
behavior to brain regions [21–23], evaluating the effects of
pharmacological treatments [24, 25], and image-guided
therapy (IGT) [26–28].
An important clinical application is the provision of
functional and anatomical data for diagnosis of neuropsy-
chiatric disorders [3, 4]. In another PubMed search on
these 1461 publications, using the keywords ‘(multimodal
AND neuroimaging) AND (neuropsychiatric OR neuro-
logical OR psychiatric),’ a substantial proportion (over
30%) of the relevant results focused on the neuropsychi-
atric disorders (see blue area in Fig. 1). The number of
publications dramatically increased each year from 10 to
121 in the period 2004–2014.
Previous reviews mainly focused on a single neuropsy-
chiatric disorder, and summarize the image-based findings
of them. For Alzheimer’s disease (AD), for example, Perrin
briefly reviewed the multimodal techniques, including
PET, fMRI, structural MRI (sMRI), and biochemical
examination of cerebrospinal fluid (CSF), to detect AD
pathology [29]. Ewers et al. integrated the findings on
changes in cortical gray matter volume, white matter fiber
tracts, and brain metabolism of patients [30], and dis-
cussed the sequential changes in neuroimaging biomarkers
during different disease stages [31], similar to the review
of Lin et al. [32]. In a more recent review, Nasrallah et al.
extended a review to other forms of neurodegenerative
dementia [33]. More in-depth reviews on other neu-
ropsychiatric disorders can be found in Sect. 3.
The goal of this review differs from those above in that
our interest is to review the recent advances in multimodal
neuroimaging and evaluate its applications in neuropsy-
chiatric disorders. Such a review will provide a clearer
picture of the current status and offer insights and inspi-
ration to researchers as they design better models/methods
for future research.
An extensive review of the image-based findings in
neuropsychiatric disorders is beyond the scope of this
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Fig. 1 The explosive growth of
multimodal neuroimaging
studies over the past two
decades. (Color figure online)
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paper, and we instead review recent studies with a focus on
the applications of multimodal neuroimaging, and refer the
readers to other reviews for the detailed findings. In
Sect. 2, we provide an overview of the common multi-
modal neuroimaging techniques, and analyze the spatial/
temporal resolution, functional/structural connectivity,
sensitivity/specificity to brain changes, risks/benefits for
clinical applications, computing workflows, and future
potential. In Sect. 3, we discuss how these neuroimaging
techniques can complement each other, and how they are
applied in neuropsychiatric disorders. In Sect. 4, we outline
future directions for multimodal neuroimaging in neu-
ropsychiatric research.
2 An overview of neuroimaging techniques
The different neuroimaging techniques have different bio-
physical/biochemical mechanisms, and vary in imaging
capabilities. Current neuroimaging techniques could be
broadly classified into functional and structural neu-
roimaging. For example, sMRI reveals the detailed anat-
omy of the brain, and diffusion MRI (dMRI) provides
information about fiber tracts. Functional modalities,
including fMRI, PET, and EEG/MEG, provide data in
brain metabolism and neural activity.
In the following paragraphs, we briefly summarize these
neuroimaging techniques with respect to
• spatial resolution; exploring the brain anatomy and
detecting morphological changes
• temporal resolution; monitoring neural activities and
interactions, tracing information pathways
• structural connectivity; tracing the major brain white
matter pathways
• functional connectivity; recording the neural co-activa-
tion, in the resting state
• molecular imaging; detecting the molecular activity
using agents to target specific functions
• safety and risks
• clinical availability, accessibility, and ease of use
• future developments
2.1 Structural MRI (sMRI)
sMRI includes a range of sequences—T1, T2, FLAIR, pro-
ton density [34]—that provide detailed information of brain
structure, and sMRI is critical for the management of neu-
ropsychiatric disorders. sMRI has spatial resolution up to
0.32 mm (isotropic) [12]. As shown in Fig. 2, sMRI,
however, does not provide connectivity information. Cur-
rently, there are approximately 25,000 MRI scanners in use
worldwide [35]. MRI is generally a safe procedure in
patients who do not have implanted devices, such as pace-
makers and implantable defibrillators [36], although there
are new MRI compatible pacemakers/defibrillators that have
been introduced [37]. MRI uses magnetic and radio waves
to generate images, rather than ionizing radiation like X-ray
or gamma ray. There are no known harmful side-effects
associated with temporary exposure to strong magnetic field
and radio waves used by MRI scanners. The narrow bore of
MRI scanners is problematic for patients who are claustro-
phobic or overweight.
When certain contrast agents, mainly iron-oxide-based,
are used, sMRI can detect the activity of the targeted
molecules with high sensitivity and specificity. Gauberti
et al. recently gave a detailed review of the recent advances
in ‘molecular’ MRI highlighting molecules that play an
important role in neuroinflammation and which may be
used as therapeutic targets and biomarkers for neurological
disorders [38]. sMRI is a mature technique used in scien-
tific and clinical applications for decades; yet there are still
many new developments, i.e., new pulse sequences, new
contrast agents, ultra-high magnetic field, and hybrid
scanners, all of which offer new imaging opportunities.
2.2 Diffusion MRI (dMRI)
dMRI is a MRI sequence that encodes molecular diffusion
effects in the nuclear magnetic resonance signal by using
bipolar magnetic field gradient pulses [39]. DTI is a form of
diffusion imaging where fiber tracts can be delineated based
on the fractional anisotropy [40] and is currently the only
technique that allows us to trace the brain white matter
pathways in vivo, as shown in Fig. 2—dMRI. By probing at
many different orientations, dMRI is able to estimate the
orientation of axonal fiber bundles, based on the fact that
water diffuses most rapidly along the length of axons. This
also leads to longer scanning time as compared to sMRI.
Currently, dMRI is used as a research tool in laborato-
ries, and has not been evaluated in clinical trials due to the
crossing-fiber problems, the differences in signal estima-
tion models and fiber tracking algorithms, the variations in
datasets, and the lack of ground truth. Nevertheless, DTI is
used clinically in the pre-operative planning prior to sur-
gical resection of gliomas which usually displace but can
involve the fiber tracts. New models and methods are
proposed each year, e.g., the q-space trajectory imaging
(QTI) [41]. Large-scale datasets with uniformly collected
dMRI data are also growing in size, and will facilitate the
evaluation of these models and methods [42].
2.3 Functional MRI (fMRI)
fMRI is a MRI technique that can depict brain activity by
detecting the associated changes in brain hemodynamics. It
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uses blood-oxygen-level-dependent (BOLD) contrast that
is closely related to cerebral blood flow (CBF), as brain
function requires blood flow to supply oxygen for energy
consumption by neurons. It has relatively high spatial
resolution (2mm isotropic) and medium temporal resolu-
tion (minutes) for a set of successive scans. Similar to
sMRI, fMRI can be used to label specific molecules with
contrast agents [43], i.e., molecular fMRI [44]. fMRI is
used clinically to identify eloquent cortex prior to surgery,
e.g., identifying the motor cortex prior to resection of a
glioma in the posterior frontal lobe. Two particular
strengths of fMRI are that it is able to detect brain acti-
vation induced by a task, and provide the connectivity
between populations of neurons based on their co-activa-
tion at resting state. These two benefits essentially define
the two categories of fMRI analyses, task-evoked fMRI
and resting-state fMRI.
When the brain is performing a task, CBF usually
changes as neurons work to complete the task. The primary
use of task-evoked fMRI is to identify the correlation
between brain activation/interaction pattern and cognitive
states, such as perception, language, memory, emotion, and
thought [45, 46]. Recent research based on task-evoked
fMRI indicated that altered cognitive functions are related to
neuropsychiatric disorders. For instance, emotion regulation
capability is not sustained in depressed patients as compared
to healthy control subjects [47]. Resting-state fMRI is used
to detect the spontaneous activation pattern in the absence of
an explicit task or stimuli [48]. Resting-state fMRI enables
us to deduce the functional connectivity between dispersed
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Fig. 2 The overview of the properties of sMRI (blue), dMRI (green),
fMRI (orange), PET (red), EEG (violet), and multimodal neuroimaging
(gray), as indicated by the polar diagrams. Each axis in the diagram
represents an attribute, and greater distance from the origin means better
performance. Note the indexes in the diagrams are merely indicative and
should not be interpreted in a quantitative way. (Color figure online)
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brain regions, which form functional brain networks, or
resting-state networks (RSNs). The default mode network
(DMN) is a functional network of several brain regions that
show increased activity at rest and decreased activity when
performing a task [49]. DMN has been widely used as a
measure to compare individual differences in behaviors,
genetics, and neuropathologies, although the use of it as a
biomarker is controversial [50, 51].
Recent improvements in spatiotemporal resolution of
fMRI have led to higher statistical power to detect RSNs.
Further investigation is needed to derive the neuropsychi-
atric biomarkers from the network and/or network
dynamics, and further evaluate them for the diagnosis of
individual neuropsychiatric disorders and to guide therapy.
2.4 Positron emission tomography (PET)
PET is the most powerful and versatile approach to study
neurotransmitter/receptor interactions. It has lower spa-
tiotemporal resolution when compared to MRI, and
involves injection of a radioactive tracer and exposure to
ionizing radiation. PET is inherently a molecular imaging
technique, which is exquisitely sensitive for detecting the
targeted molecules or processes. For example, 2-[18F]flu-
oro-2-deoxy-D-glucose (FDG) is the most widely used
radiotracer that can assess the glucose metabolism in brain,
thus has been used for diagnosis, staging, and monitoring
treatment of cancers [52] and neurodegenerative disor-
ders [53]. In recent years, the percentage of FDG-PET
brain studies have decreased due to the introduction of new
tracers, e.g., the amyloid-binding compounds, 18F-BAY94-
9172, 11C-SB-13, 11C-BF-227, 18F-AV-45, and 11C-Pitts-
burgh compound B (11C-PiB). There are a number of
reviews of amyloid imaging agents [29, 54–56].
2.5 Electroencephalography (EEG)
and magnetoencephalography (MEG)
EEG and MEG detect the synchronized activity of an
assembly of neurons by displaying their weighted sum of
instantaneous neuronal electrical current or magnetic fluxes
throughout the brain. EEG and MEG are widely used in
neurology clinics due to the simplicity and mobility of
EEG monitoring systems, both are safe procedures. EEG
and MEG allow us to explore brain cortical activation
pattern with ultra-high temporal resolution and record the
event-evoked neural information flow in real time. How-
ever, EEG and MEG are limited by the low spatial reso-
lution and specificity, and the inability to detect and record
the signals from subcortical regions.
An important opportunity for the future is the integration
of EEG and MEG with MRI, in particular, with fMRI. EEG
and MEG are able to demonstrate the brain activation at
much greater temporal resolution when compared to MRI.
The MRI produces the anatomical template which enhan-
ces the inherent poor spatial resolution of EEG and MEG
source images. However, a major challenge has been to
develop EEG and MEG technology that can operate in a
high magnetic field. Other challenges exist to better
understand the correlation between BOLD signals and
electrophysiological events via neurovascular coupling and
enhance performance of EEG source imaging from
simultaneously acquired fMRI data.
2.6 Multimodal neuroimaging
Multimodal neuroimaging, which we refer to as the col-
lective information offered in multiple imaging modalities,
has become a major driver for current research due to the
awareness of the clinical benefits of the multimodal data.
As shown in Fig. 2, multimodal data analysis could take
the advantages from multiple imaging techniques, e.g.,
improving both spatial and temporal resolution, finding the
anatomical basis for functional connectivity, targeting
disease biomarkers with high specificity and sensitivity,
along with many new opportunities to improve brain
research. Multimodal neuroimaging is currently limited by
the availability and safety of the imaging scanners, but
novel neuroimaging scanners, especially the hybrid scan-
ners, such as PET/CT and EEG/MRI, will become more
widely available in the midrange future. Multimodal neu-
roimaging analysis is much more challenging than single
modality analysis, as multimodal neuroimaging requires
sophisticated computing methods, i.e., pre-processing,
feature extraction, image fusion, machine learning, visu-
alization, and post-processing, to tackle the large variations
in the spatiotemporal resolution and integrate the bio-
physical/biochemical information of the multimodal data.
Many multimodal neuroimaging computing methods have
been proposed and applied to a wide range of clinical and
non-clinical applications, e.g., brain computer communi-
cation [19], information pathways tracing [20], brain
mapping [21–23], drug development and discovery [24,
25], pre-operative surgical planning, and intra-operative
surgical navigation [28, 57].
As shown in Fig. 1, there has been explosive growth in
multimodal neuroimaging approaches during the last dec-
ade, and we may foresee such growth in the following
years.
3 Applications to neuropsychiatric disorders
Neuropsychiatric disorders represent the most disabling
and costly category, based on the systematic analysis of
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descriptive epidemiology of 291 diseases and injuries from
1990 to 2010 for 187 countries [58]. As shown in Fig. 3,
neuropsychiatric disorders caused the largest number of
years lost due to illness, disability, and early death mea-
sured by disability-adjusted life years (DALYs) in US, and
the socioeconomic burden of neuropsychiatric disorders
will be aggravated as people live longer.
Neuroimaging techniques have expanded beyond a tra-
ditional diagnostic role to have a fundamental role in
patient management from diagnosis, to selection and
assessment of treatment and to prognosis stratification.
There is a rising trend of using the multimodal neu-
roimaging approaches in neuropsychiatric disorders, as
shown in Fig. 1. In this section, we summarize how these
neuroimaging techniques can be integrated using the mul-
timodal computing methods, and further demonstrate their
applications in neuropsychiatric disorders as well as in
stroke, traumatic brain injury (TBI), brain tumors, and the
brain connectome (Fig. 4).
These multimodal approaches can be separated into
categories that include a structural–structural combination,
a functional–functional combination, and a structural–
functional combination. Each category has different
applications, and requires different computing workflows.
In brief, a structural–structural combination, e.g., sMRI-
dMRI, is used to extract and fuse various morphological
features and is applied to disorders that affect both gray
matter and white matter, such as TBI and stroke. The
functional–functional combination can be used to explore
brain activation/metabolism patterns and is mainly applied
to cognition and consciousness-related disorders, e.g.,
epilepsy and obsessive-compulsive disorder (OCD). The
structural–functional combination is virtually applicable to
all disorders, but more frequently used for identifying the
structure–function associations in neurodegenerative dis-
orders, neurodevelopmental disorders, multiple sclerosis,
schizophrenia, bipolar disorder, brain tumors, and the brain
connectome.
3.1 Structural–structural combination
sMRI-dMRI methods dominate the structural–structural
category, as they take clinical benefits of sMRI and dMRI
by integrating the gray matter and white matter mor-
phometry. It has become a useful tool to detect lesions and
evaluate treatments for various neuropsychiatric disorders
that cause brain morphological changes. Here, we list a few
examples of clinical uses of sMRI-dMRI.
Traumatic brain injury (TBI) has very high incidence,
resulting in 6.8 million TBI cases every year in the US, and
causes impairment of memory, information processing,
attention, and executive function [59]. Multimodal struc-
tural neuroimaging can assist neurosurgeons, intensive care
specialists, neurologists, and rehabilitation specialists in
the management of TBI [60]. Conventional brain CT
usually fails to detect the subtle structural abnormalities in
mild TBI, and sMRI and dMRI are the methods of choice
to evaluate and predict outcome in TBI. The sMRI
sequences (T1, T2, FLAIR, susceptibility-weighted imag-
ing (SWI) and gradient-recalled echo (GRE)) provide
highly accurate depiction of pathological lesions, and
dMRI detects the effects of TBI on brain connectivity and
non-hemorrhagic diffuse axonal injury (DAI), which are
not detected by CT. The sMRI-dMRI methods are widely
used in TBI [61, 62]. There are also some studies that have
used dMRI and fMRI to validate the connectivity infor-
mation in TBI patients in the recovery phase [63, 64].
The sMRI-dMRI methods have been routinely used in
the assessment and treatment planning for stroke. Stroke is
a leading cause of death worldwide. There are different
types of stroke, and each requires a different diagnostic
approach and treatment. T2*-weighted sMRI, e.g., SWI
and GRE, is primarily used to detect hemorrhagic stroke,
and has equal sensitivity to standard CT methods. How-
ever, dMRI is 4-5 times more sensitive in detecting acute
ischemic stroke than CT. Other structural imaging tech-
niques, such as perfusion CT (PCT), CT angiography
NeurologicalPsychiatric
Fig. 3 The disability-adjusted life years (DALYs) of 291 diseases and injuries based on the systematic analysis of descriptive epidemiology from
1990 to 2010 in US [58]. (Color figure online)
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(CTA), digital subtraction angiography (DSA), perfusion-
weighted imaging (PWI), and MR angiography (MRA),
can also be used to evaluate suspected vascular occlusion,
edema, and cerebral infarction. Tong et al. [65] recently
published a comprehensive comparison of these methods in
the evaluation and management of stroke. Another review
on multimodal neuroimaging in stroke is given by Copen
et al. [66].
sMRI-dMRI methods have also been used to analyze the
gray and white matter alterations in schizophrenia [67]
and Autism spectrum disorders (ASDs) [16, 68], neu-
rodegeneration simulation [69], classification of AD and
frontotemporal dementia (FTD) [70], and Parkinson’s
Disease (PD) staging [71].
3.2 Functional–functional combination
EEG-fMRI is valued in functional brain research due to the
complementary nature of EEG and fMRI. EEG-fMRI can
provide simultaneous cortical and subcortical recording of
brain activity with high spatiotemporal resolution.
Epilepsy is one of the most prevalent neurological dis-
orders worldwide. EEG-fMRI is increasingly used to pro-
vide clinical support for the diagnosis of epilepsy, in
Epilepsy
ADHD
Bipolar DisorderMultiple Sclerosis
OCD
Brain Tumor
Schizophrenia
Connectome
ASD
Stroke
CT
CTA MRA
DSA
PCT PWI
TBI
CT
Fig. 4 The applications of the multimodal neuroimaging approaches
in a variety of neuropsychiatric disorders, as well as in stroke, brain
injury, brain tumor, and connectome. The color of circle indicates
various neuroimaging techniques, same as in Fig. 2. The size of the
circle indicates the prevalence of use the technique in specific
applications. Note the sizes are only indicative and should not be
interpreted in a quantitative way. (Color figure online)
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addition to the routinely used sMRI [72] and PET [14,
73]. Researches have used EEG-fMRI to identify a set of
brain functional regions that collectively form ‘conscious-
ness,’ including contributions from the DMN, ascending
arousal systems, and the thalamus, as summarized by
Bagshaw et al. [74]. The activation of these regions and
the connection of the networks are important in the eval-
uation of epilepsy, and together may provide a more fun-
damental understanding of the alterations of consciousness
experienced in epilepsy. Abela et al. [75] focused on
altered network compositions in epilepsy, and identified the
specific connectivity pathways that characterize the
underlying epilepsy syndromes, such as mesial temporal
lobe epilepsy (MTLE), lateral temporal lobe epilepsy
(LTLE), frontal lobe epilepsy (FLE), idiopathic general-
ized epilepsy (IGE), and absence epilepsy (AE). A sub-
stantial proportion of patients have refractory epilepsy and
surgery offers the potential to reduce seizure frequency.
Successful surgical treatments, however, require accurate
localization of the seizure onset zones and an understand-
ing of surrounding functional cortex to avoid iatrogenic
disability. PET, MRI, and intracranial EEG (iEEG) are all
needed for optimal surgical planning and treatment eval-
uation of refractory epilepsy [76, 77].
Another important application of EEG-fMRI is to
evaluate patients with obsessive-compulsive disorder
(OCD). OCD is a chronic and relatively common neu-
ropsychiatric disorder that characterized by stereotyped
and repetitive behaviors. Patients with OCD feel intense
need to carry out these behaviors, and have impaired ability
to recognize an error and to adjust future responses. OCD
may result in social disability. Two neuroimaging
biomarkers of error commission, the error-related nega-
tivity (ERN) and the dorsal anterior cingulate cortex acti-
vation, have been identified using EEG and fMRI,
respectively [78]. However, Agam et al. [79] recently
suggested that these biomarkers have different neural and
genetic mediation. dMRI is also increasingly being used to
examine the microstructural integrity of white matter in
OCD patients, since white matter abnormalities have long
been suspected in OCD, but the findings are inconsistent.
For example, one recent study indicated that patients with
OCD had decreased fractional anisotropy in the anterior
cingulum bundle [80], but in another recent study, the
OCD patients showed increased fractional anisotropy of the
cingulum bundle [81]. Further investigation on large
datasets is needed to confirm these findings.
3.3 Structural–functional combination
sMRI-dMRI-fMRI has been ubiquitously used in neu-
ropsychiatric research largely because of high clinical
availability, and partially due to its capability to link brain
function, structure, and connectivity. It has been increas-
ingly used in research in attention-deficit hyperactivity
disorder (ADHD), Autism spectrum disorder (ASD),
bipolar disorder, schizophrenia, and clinically in multiple
Sclerosis (MS).
ADHD is one of the most commonly diagnosed child-
hood behavioral disorders. It is characterized by persistent
inattention (ADHD-I), hyperactivity-impulsivity (ADHD-
H), or a combination of both (ADHD-C). ADHD affects at
least 5–11% of school-age children, and symptoms may
persist into adulthood [82]. Previous studies using sMRI
have reported various findings, such as decreased total
brain volume and abnormalities in specific brain regions.
The task-evoked and resting-state fMRI approaches were
also used in ADHD studies to detect the abnormal brain
activation. The use of sMRI and fMRI was reported
recently in ADHD [83, 84]. It is only quite recently that
dMRI has been applied to ADHD to characterize the dis-
rupted interconnected structural networks in the brain.
Shenton et al. provided a brief summary of the latest
studies [85]. For example, Hong et al. used dMRI and
whole-brain tractography to investigate the altered white
matter connectivity in 71 children with ADHD, and iden-
tified a single network (comprising 23 brain regions and 25
links) that differentiates the ADHD group from the normal
control group [86].
ASDs are neurodevelopmental disorders characterized
by deficits in social reciprocity, impaired communication,
and restricted interests and repetitive behaviors. Previous
studies using sMRI have shown that infants with ASD
might have excessive brain growth followed by abnormally
slow or even arrested growth as compared to normal
developing control infants in early childhood [87]. Sub-
sequent research indicated ASD affects both gray and
white matter volumes. Therefore, dMRI has been exploited
to describe the microstructural integrity and orientation of
white matter. fMRI has enhanced the understanding of the
neural circuity of ASDs by demonstrating the convergent
structural and functional changes [88, 89]. For example,
Mueller et al. used sMRI-dMRI-fMRI approach and iden-
tified three brain areas with strong correlations between the
structural and functional abnormalities: right tem-
poroparietal junction and the left frontal lobe, bilateral
superior temporal gyri, and the right temporoparietal
region [90].
MS is a demyelinating disease commonly seen in young
people. The cause of MS is unknown. Symptoms and signs
vary across patients and can include cognitive impairment,
fatigue, vertigo, diplopia, ataxia, hemiparesis, and para-
paresis in severe MS patients. Histopathologic and neu-
roimaging examinations suggest that both white matter and
gray matter are affected. In particular, the thalamus can be
affected frequently in MS [91], which can lead to impaired
174 S. Liu et al.
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cognition. sMRI can detect the thalamic atrophy; dMRI can
be used to demonstrate the altered thalamocortical white
matter pathways, and fMRI can be used to show the
association between the resting-state thalamocortical
functional connectivity and cognitive impairment.
Recently, sMRI-dMRI-fMRI was jointly used in several
studies [92, 93].
Bipolar disorder is a psychotic disorder that characterized
states of depression and mania, and sometimes with symp-
toms common to schizophrenia. It is therefore difficult to
conceptualize bipolar disorder and its subtypes, and differ-
entiate it from other psychiatric disorders. The multimodal
MRI methods have been applied to bipolar disorder and
clearly demonstrate abnormalities in brain networks associ-
ated with emotion processing, emotion regulation, and reward
processing. In a recent study, Sui et al. proposed a joint
analysis model for fMRI and DTI for discriminating bipolar
disorder from schizophrenia [94]. Common abnormalities
were seen in dorsolateral prefrontal cortex, thalamus, and
uncinate fasciculus, whereas differences were found in medial
frontal and visual cortex, as well as occipitofrontal white
matter tracts. Phillips and Swartz recently published an
extensive review of these neuroimaging findings and further
pointed out the future directions of neuroimaging research in
bipolar disorder [95].
Schizophrenia is a major psychosis that is characterized
by altered perception, thought processes, and behaviors. It
can be highly heritable disorder [96], and can be triggered
by a combination of genetic factors and environmental
interactions [97]. Disconnection in white matter pathways
and alteration of cortex are assumed to underlie the cog-
nitive abnormalities in schizophrenia, although this is a
hypothesis and as yet there is no direct proof. The
approaches used for characterizing schizophrenia are very
similar to those for bipolar disorder, primarily using sMRI-
dMRI-fMRI. Various findings in schizophrenia studies
have been reported, based on the investigation on
microstructure of white matter [98] or gray matter [97], or
the connectivity between different brain regions [67, 99].
The study of brain networks, the connectome, is the
focus of intense current neuroscience research [100].
Exploration on the neural systems and brain connections is
critical to advance our understanding of normal brain
reaction and is one of the greatest challenges of the twenty
first century. The Human Connectome Project1 is directed
at tackling this challenge using the highest quality imaging
data available today, predominantly MRI data, comple-
mented by EEG and MEG. The information about brain
anatomy, structural connectivity, and functional connec-
tivity is being obtained using dMRI and resting-state fMRI.
Additional information about brain function is being
obtained using task-evoked fMRI, EEG, and MEG to
record the brain activity.
sMRI-PET is a new structural–functional combination
that is being applied to neurodegenerative diseases and
brain tumors to improve the localization and targeting of
diseased tissue with high accuracy and sensitivity. AD is
the most common neurodegenerative disorder among aging
people, and it accounts for close to 70% of all dementia
cases. In AD, activities of daily living deteriorate over a
number of years, ultimately leading to death. There is no
cure [101]. AD neuroimaging biomarkers can detect the
changes in brain structure (e.g., atrophy on sMRI) and
function (e.g., hypometabolism, amyloid plaque, and NFT
formation on PET) before there is cognitive impairment.
As a result, sMRI and PET with 18F-FDG and amyloid
tracers are being increasingly used in the evaluation of
patients with early dementia in the research setting [8,
102–106]. These studies also demonstrated clear benefits of
multimodal neuroimaging over any single technique alone.
Recently, dMRI [107, 108] and fMRI [109] have also
been used in the evaluation of dementia as there is evi-
dence that suggests the functional connection between
networks is disrupted [110–112]. There are many exten-
sive reviews which summarized these imaging techniques
and the image-based findings [29–31, 33].
Over 200,000 individuals are diagnosed with primary or
metastatic brain tumors in the US each year [28]. The
primary use of sMRI-PET in brain tumors is to accurately
localize and label the lesion, e.g., tumor and edema. PET
has the potential to more accurately detect the peripheral
tumor boundary than using sMRI alone [11, 113]. For
brain tumor surgery, dMRI is usually combined with sMRI
and PET for pre-operative surgical planning and intra-
operative surgical navigation. For example, Durst et al.
used dMRI to predict tumor infiltration in patients with
gliomas [114]. Tempany et al. used sMRI and dMRI
tractography to display a complete brain map for surgical
planning [28]. They further demonstrated how to optimize
the separation between tumor and normal brain in intrinsic
brain tumors with sMRI, and how to avoid inadequate
resection of the tumor.
4 Future directions
Multimodal neuroimaging approaches have been increas-
ingly used in detection, diagnosis, prognosis, and treatment
planning of neuropsychiatric disorders. In this paper, we
have briefly summarized the recent advances in neu-
roimaging techniques, and reviewed their applications to
neuropsychiatric disorders to provide an overview of the
current status. We have also outlined some future direc-
tions for multimodal neuroimaging research.1 http://www.neuroscienceblueprint.nih.gov/connectome
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Improved neuroimaging capabilities Neuroimaging
techniques will continue to advance rapidly, with higher
spatial/temporal/angular resolutions, shorter scan time, and
better image contrast. In particular, hybrid scanners, e.g.,
PET/CT and PET/MRI, will become more clinically
accessible. These technologies will enable more discover-
ies in the neuropsychiatric disorders. The improved imag-
ing capabilities will offer better neuroimaging biomarkers
to evaluate neuropsychiatric disorders, and various sub-
types or different stages of the same disorder with higher
statistical power. These biomarkers will be standardized so
they can be widely used clinically and evaluated in large-
scale sample sets. In addition, once the biomarkers reach a
satisfactory level or the treatment, appropriate clinical
guidelines must be developed to support and encourage
widespread clinical testing.
Enhanced neuroimaging computing models and methods
The continued growth in the complexity and dimension-
ality of the neuroimaging data will spur the parallel
advances of computation models and methods to analyze
such complex data. Future neuroimaging analysis models
will integrate the longitudinal information to track the
long-term changes in the biomarkers [115]. This is essen-
tial for us to understand the pathology of the disorders and
its degeneration trajectory. With sufficiently large longi-
tudinal datasets, we may be able to identify the causes and
detect the early signs, as well as predict the course of the
disorders. Future studies will also focus on subject-cen-
tered therapy. However, no matter how large the datasets
are, they cannot include the entire population, and there
will always be inter-subject variations. Personalized/pa-
tient-centered care is highly demanded and is the ultimate
goal of neuroimaging studies [116]. Neuroimaging com-
puting models and methods also need to keep increasing
the degree of automation, accuracy, reproducibility, and
robustness, and eventually need to be integrated into the
clinical workflow to facilitate clinical testing of the new
neuroimaging biomarkers.
Converged neurotechnologies Another future direction
will be to combine imaging with non-imaging studies. The
multidisciplinary nature of neuroimaging computing will
keep bringing together clinicians, biologists, computer
scientists, engineers, physicists, and other researchers.
Imaging genetics is a very promising area for the future,
where the aim is to identify the genetic basis of anatomical
and functional abnormalities of the human brain and show
how this is connected with neuropsychiatric disorders.
There is a trend to use imaging findings in brain disorders
to reveal the endophenotypes for various gene mutations.
By converting the endophenotype data to novel genetic
biomarkers, it may be possible to identify individuals at
greater risk of developing brain disorders, and in the near
future provide treatment options before the symptoms
appear.
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